These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29302031)

  • 21. Stem cell maintenance and disease progression in chronic myeloid leukemia.
    Ito T
    Int J Hematol; 2013 Dec; 98(6):641-7. PubMed ID: 23550022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML.
    Toda J; Ichii M; Oritani K; Shibayama H; Tanimura A; Saito H; Yokota T; Motooka D; Okuzaki D; Kitai Y; Muromoto R; Kashiwakura JI; Matsuda T; Hosen N; Kanakura Y
    Oncogene; 2020 Aug; 39(34):5601-5615. PubMed ID: 32661325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
    Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
    Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signaling pathways in chronic myeloid leukemia and leukemic stem cell maintenance: key role of stromal microenvironment.
    Seke Etet PF; Vecchio L; Nwabo Kamdje AH
    Cell Signal; 2012 Sep; 24(9):1883-8. PubMed ID: 22659137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.
    Vicente-Dueñas C; Barajas-Diego M; Romero-Camarero I; González-Herrero I; Flores T; Sánchez-García I
    Oncotarget; 2012 Mar; 3(3):261-6. PubMed ID: 22408137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.
    Jaroslav P; Martina H; Jirí S; Hana K; Petr S; Tomás K; Julius M; Cedrik H
    Leuk Lymphoma; 2005 Nov; 46(11):1605-1612. PubMed ID: 16334487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
    Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological and In Vivo Microscopic Analysis of the Bone Marrow Microenvironment in a Murine Model of Chronic Myelogenous Leukemia.
    Weissenberger ES; Krause DS
    Methods Mol Biol; 2016; 1465():59-72. PubMed ID: 27581139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches.
    Krenn PW; Koschmieder S; Fässler R
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24326-24335. PubMed ID: 32929022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
    Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
    Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.
    Xishan Z; Guangyu A; Yuguang S; Hongmei Z
    J Exp Clin Cancer Res; 2011 May; 30(1):47. PubMed ID: 21535879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.
    Lei H; Xu HZ; Shan HZ; Liu M; Lu Y; Fang ZX; Jin J; Jing B; Xiao XH; Gao SM; Gao FH; Xia L; Yang L; Liu LG; Wang WW; Liu CX; Tong Y; Wu YZ; Zheng JK; Chen GQ; Zhou L; Wu YL
    Nat Commun; 2021 Jan; 12(1):51. PubMed ID: 33397955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine phosphorylation of proteins in primary human myeloid leukemia cells stimulated by cytokines: analysis of the frequency of phosphorylation, and partial identification and semi-quantification of signaling molecules.
    Hagiwara S; Iki S; Urabe A; Saeki K; Miwa A; Togawa A; Ozawa K; Takaku F; Yuo A
    Int J Hematol; 1998 Dec; 68(4):387-401. PubMed ID: 9885438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
    Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
    PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
    Dierks C; Beigi R; Guo GR; Zirlik K; Stegert MR; Manley P; Trussell C; Schmitt-Graeff A; Landwerlin K; Veelken H; Warmuth M
    Cancer Cell; 2008 Sep; 14(3):238-49. PubMed ID: 18772113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
    Qiao J; Liang C; Zhao D; Nguyen LXT; Chen F; Suo S; Hoang DH; Pellicano F; Rodriguez IR; Elhajmoussa Y; Ghoda L; Yoshimura A; Stein AS; Ali H; Koller P; Perrotti D; Copland M; Han A; Zhang BA; Marcucci G
    Leukemia; 2022 Feb; 36(2):492-506. PubMed ID: 34564700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
    Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.